These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9199822)

  • 1. Factor V antigen levels in APC resistance, in factor V deficiency and in combined APC resistance and factor V deficiency (pseudohomozygosis for APC resistance).
    Girolami A; Simioni P; Venturelli U; Girolami B; Zanon E
    Blood Coagul Fibrinolysis; 1997 Jun; 8(4):245-8. PubMed ID: 9199822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
    Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homozygous factor V-deficient patients show resistance to activated protein C whereas heterozygotes do not.
    Simioni P; Girolami A
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):825-7. PubMed ID: 7865690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
    Delahousse B; Iochmann S; Pouplard C; Fimbel B; Charbonnier B; Gruel Y
    Blood Coagul Fibrinolysis; 1997 Nov; 8(8):503-9. PubMed ID: 9491268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
    Guasch JF; Lensen RP; Bertina RM
    Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemorrhagic and thrombotic disorders due to factor V deficiencies and abnormalities: an updated classification.
    Girolami A; Simioni P; Scarano L; Girolami B; Marchiori A
    Blood Rev; 1998 Mar; 12(1):45-51. PubMed ID: 9597197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor V Leiden, activated protein C resistance, and retinal vein occlusion.
    Ciardella AP; Yannuzzi LA; Freund KB; DiMichele D; Nejat M; De Rosa JT; Daly JR; Sisco L
    Retina; 1998; 18(4):308-15. PubMed ID: 9730172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
    Reuner KH; Litfin F; Patscheke H
    Eur J Clin Chem Clin Biochem; 1997 Jan; 35(1):41-5. PubMed ID: 9156566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency.
    Zehnder JL; Jain M
    Blood Coagul Fibrinolysis; 1996 Apr; 7(3):361-2. PubMed ID: 8735145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
    Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G
    Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of rivaroxaban influence on a prothrombinase-based assay for the detection of activated C protein resistance: an Italian ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
    Gessoni G; Valverde S; Valle L; Gessoni F; Caruso P; Valle R
    Int J Lab Hematol; 2017 Aug; 39(4):418-422. PubMed ID: 28318106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method.
    Hoagland LE; Triplett DA; Peng F; Barna L
    Thromb Res; 1996 Sep; 83(5):363-73. PubMed ID: 8873345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease.
    Zöller B; He X; Dahlbäck B
    Thromb Haemost; 1995 May; 73(5):743-5. PubMed ID: 7482396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation.
    Simioni P; Scarano L; Gavasso S; Sardella C; Girolami B; Scudeller A; Girolami A
    Br J Haematol; 1996 Feb; 92(2):435-41. PubMed ID: 8603014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations of a calibrated, quantitative APC-R assay under routine conditions.
    Jilma-Stohlawetz P; Lysy K; Sunder-Plassmann R; Belik S; Jilma B; Pabinger I; Quehenberger P
    Int J Lab Hematol; 2021 Apr; 43(2):318-323. PubMed ID: 33131213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
    De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
    Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
    De Stefano V; Leone G
    Haematologica; 1995; 80(4):344-56. PubMed ID: 7590506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thrombosis: factor V G1691A genotyping related to APC resistance as measured by 2 methods.
    Alderborn A; Siegbahn A; Wadelius C
    Eur J Haematol; 1997 Apr; 58(4):229-32. PubMed ID: 9186532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
    Zöller B; Svensson PJ; He X; Dahlbäck B
    J Clin Invest; 1994 Dec; 94(6):2521-4. PubMed ID: 7989612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.